GT BIOPHARMA INC (GTBP)

GTBP Stock Earnings: GT Biopharma Beats EPS for Q4 2023

GTBP stock results show that GT Biopharma beat analyst estimates for earnings per share the fourth quarter of 2023.

GTBP Stock Earnings: GT Biopharma Beats EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips GT Biopharma (NASDAQ:GTBP) just reported results for the fourth quarter of 2023...

GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results

Remain in active dialogue with the FDA regarding IND clearance for GTB-3650, a 2nd generation nanobody TriKE® for treatment of CD33+ leukemiaPhase 1 trial...

GT Biopharma announces 1-for-30 reverse stock split (NASDAQ:GTBP)

GT Biopharma announces 1-for-30 reverse stock split to regain compliance with Nasdaq listing requirements.

GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split

BRISBANE, CALIFORNIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) (the “Company”), a clinical stage immuno-oncology company...

Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders

The deadline for stockholders to vote (or change their vote) is 11:59 p.m. EST on Sunday, December 17, 2023 BRISBANE, California, Dec....

GT Biopharma submits IND to FDA for CD33+ leukemia therapy (GTBP)

GT Biopharma (GTBP) has submitted an Investigational New Drug application to the FDA for GTB-3650 in the treatment of CD33+ leukemia, including AML and MDS. Read more here.

GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia

BRISBANE, CALIFORNIA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

It's time for another dive into the biggest pre-market stock movers as we break down all of the latest news for Tuesday morning.

GT Biopharma Reports Second Quarter 2023 Financial Results

Cash of approximately $18.0 million as of June 30, 2023, provides ample runway to fund operations into Q3 2024; anticipated to be sufficient to achieve IND...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

It's time to start the day final of trading this week with an overview of the biggest pre-market stock movers on Friday morning!

GT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023

BRISBANE, CALIFORNIA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing...

GT Biopharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

Cash of approximately $19.9 million as of March 31, 2023, provides ample runway to fund operations into Q2 2024; anticipated to be sufficient to achieve...

GT Biopharma Names Charles J. Casamento to the Board of Directors

BRISBANE, CALIFORNIA, May 04, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company...

GT Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

Proforma cash of approximately $23.0 million includes $16.5 million in cash as of December 31, 2022, plus $6.5 million in gross proceeds received from a...

GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference

BRISBANE, CALIFORNIA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing...

GT Biopharma Issues Open Letter to Shareholders Detailing Recent Activities

BRISBANE, CALIFORNIA, Feb. 02, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology...

GTBP stock slips on $6.5M stock offering (NASDAQ:GTBP)

GT Biopharma (GTBP) lost ~8% pre-market Friday after announcing a registered direct offering to sell 6.5M shares of its common stock and warrants to raise $6.5M. Read the full story here.

GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering Priced At Premium To Market

BRISBANE, CALIFORNIA, Dec. 30, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology...

GT Biopharma names Dr. Jeff Miller as chief medical officer (NASDAQ:GTBP)

Clinical stage immuno-oncology company focused on developing innovative therapeutics, GT Biopharma (GTBP) based on the company's proprietary natural killer ((NK)) cell...

GT Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer

BRISBANE, CALIFORNIA, Dec. 14, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology...

GT Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer

FATE stock hits 52-week low after preclinical data on leukemia treatment (NASDAQ:FATE)

Fate Therapeutics (FATE) fell Monday after announcing preclinical data with partner GT Biopharma (GTBP) to support a new therapeutic approach for myeloid leukemia. Read the full story here.

GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022

Presentation shows the therapeutic potential of combining iPSC-derived CAR NK cells and NK cell engagers to overcome the clinical heterogeneity of AML ...